HLA-B -21位二态性影响急性髓系白血病中NK细胞教育及免疫治疗临床结局
研究比较携带HLA-B -21M或-21T的受试者NK细胞功能,发现-21M者NKG2A+NK细胞教育更佳且对KIR配体匹配的白血病原始细胞脱颗粒能力更强;在IL-2免疫治疗4期试验中,-21M患者无白血病生存和总生存优于-21T患者。
要点
- 携带HLA-B -21M的受试者具有教育更佳的NKG2A+NK细胞。
- -21M受试者NK细胞对KIR配体匹配的原发性白血病原始细胞脱颗粒能力更强。
- IL-2免疫治疗中-21M患者无白血病生存和总生存优于-21T患者。
核心结论
- HLA-B -21遗传变异可能决定活化NK细胞的抗白血病效力及NK细胞活化免疫治疗的临床获益。
研究设计与样本
- 第一部分比较携带HLA-B -21M或-21T受试者的IL-2活化NK细胞对急性髓系白血病患者白血病细胞的功能。
- 第二部分在患者接受IL-2为基础免疫治疗的4期试验中分析HLA-B -21变异对AML病程的潜在影响。
主要发现
- 携带HLA-B -21M的受试者具有教育更佳的NKG2A+NK细胞。
- 携带HLA-B -21M的受试者NK细胞对KIR配体匹配的原发性白血病原始细胞脱颗粒能力更强。
- 在IL-2为基础免疫治疗期间,-21M患者无白血病生存和总生存优于-21T患者。
临床怎么用
- 作者提出HLA-B -21遗传变异可能决定活化NK细胞的抗白血病效力及NK细胞活化免疫治疗的临床获益。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Natural killer (NK) cell function is regulated by inhibitory receptors, such as the family of killer immunoglobulin-like receptors (KIRs) and the NKG2A/CD94 heterodimer. These receptors recognize cognate HLA class I molecules on potential target cells, and recent studies imply that an HLA-B dimorphism at position -21 in the gene segment encoding the leader peptide dictates whether NK cell regulation primarily relies on the KIRs or the NKG2A/CD94 receptor. The impact of this HLA-B dimorphism on NK cell-mediated destruction of leukemic cells or on the course of leukemia is largely unknown. In a first part of this study, we compared functions of NK cells in subjects carrying HLA-B -21M or 21T using interleukin-2 (IL-2)-activated NK cells and leukemic cells from patients with acute myeloid leukemia (AML). Subjects carrying HLA-B -21M harbored better-educated NKG2A+ NK cells and displayed superior capacity to degranulate lytic granules against KIR ligand-matched primary leukemic blasts. Second, we aimed to define the potential impact of HLA-B -21 variation on the course of AML in a phase 4 trial in which patients received IL-2-based immunotherapy. In keeping with the hypothesis that 21M may be associated with improved NK cell functionality, we observed superior leukemia-free survival and overall survival in -21M patients than in -21T patients during IL-2-based immunotherapy. We propose that genetic variation at HLA-B -21 may determine the antileukemic efficacy of activated NK cells and the clinical benefit of NK cell-activating immunotherapy.
引用
- Hallner A, Bernson E, Hussein BA, et al. The HLA-B -21 dimorphism impacts on NK cell education and clinical outcome of immunotherapy in acute myeloid leukemia. Blood. 2019. PMID: 30647027. doi:10.1182/blood-2018-09-874990
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。